Loading stock data…
TENX
$12.78-0.33 (-2.52%)
Market ClosedLast close May 1
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Tenax Therapeutics, Inc. in the Healthcare sector is trading at $12.78. The stock is currently 30% below its 52-week high of $18.38, remaining 26.3% above its 200-day moving average. Technical signals show neutral RSI of 39 and bearish MACD signal, explaining why TENX maintains its current momentum and trend strength. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 39) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$12.78
Potential Upside
5%
Whystock Fair Value$13.42
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus7 analysts
Mean target$29.57+131.4%
Range$20.00 – $35.00
Fundamentals
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatme...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$239.39M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.19
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-12.06%
Volume
Today's trading volume
433,935
Recent News
Companies Like Tenax Therapeutics (NASDAQ:TENX) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. By way of example, Tenax Therapeutics...
DraftKings, Eli Lilly downgraded: Wall Street's top analyst calls
DraftKings, Eli Lilly downgraded: Wall Street's top analyst calls
Tenax Therapeutics: Q4 Earnings Snapshot
The Chapel Hill, North Carolina-based company said it had a loss of 38 cents per share. The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of $1.26 per share.
Tenax Therapeutics Shares Phase III Levosimendan Progress, H2 Data Timeline at Guggenheim Conference
Executives from Tenax Therapeutics (NASDAQ:TENX) outlined progress on the company’s Phase III development program for levosimendan in pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) during a fireside chat at Guggenheim’s Emerging Outlook Biotech Confe
Guggenheim Doubles Tenax (TENX) PT, Names Stock Top Pick
Tenax Therapeutics Inc (NASDAQ:TENX) is one of the best performing micro cap stocks in 2025. On December 17, Guggenheim raised its price target on Tenax Therapeutics Inc (NASDAQ:TENX) to $25 from $14 and maintained a Buy rating. The firm stated that its decision to nearly double the price target for Tenax relies on a specific […]